News headlines about Egalet Corporation (NASDAQ:EGLT) have been trending somewhat positive this week, according to Accern. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Egalet Corporation earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 46.3028059722884 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern’s analysis:
- Varied Analyst Comments On CVS Health Corporation (CVS), Egalet Corporation (EGLT) (fumbleboard.com)
- Investor Update: Focusing in on Shares of Egalet Corporation (NASDAQ:EGLT) – Sparta Review (spartareview.com)
- FY2017 EPS Estimates for Egalet Corporation Raised by Gabelli (EGLT) (americanbankingnews.com)
- 13G Filing: Highbridge Capital Management and Egalet Corp (EGLT) (insidermonkey.com)
- Traders Keeping Egalet Corp (EGLT) on Close Watch As Shares Move – Sparta Review (spartareview.com)
Several analysts recently weighed in on the company. Cantor Fitzgerald set a $8.00 target price on Egalet Corporation and gave the company a “buy” rating in a research note on Saturday, May 13th. JMP Securities decreased their target price on Egalet Corporation from $15.00 to $6.00 and set a “market outperform” rating for the company in a research note on Friday, July 14th. Zacks Investment Research downgraded Egalet Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, May 10th. ValuEngine downgraded Egalet Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Gabelli upgraded Egalet Corporation from a “hold” rating to a “buy” rating and set a $9.50 target price for the company in a research note on Friday, May 12th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $10.20.
Shares of Egalet Corporation (NASDAQ EGLT) traded up 1.41% during mid-day trading on Thursday, reaching $1.44. The company had a trading volume of 230,168 shares. Egalet Corporation has a 12 month low of $1.32 and a 12 month high of $10.00. The company’s market capitalization is $36.05 million. The firm’s 50-day moving average is $2.19 and its 200 day moving average is $3.97.
Egalet Corporation (NASDAQ:EGLT) last announced its quarterly earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by $0.12. The business had revenue of $5.57 million for the quarter, compared to analyst estimates of $6.92 million. Egalet Corporation had a negative return on equity of 607.49% and a negative net margin of 494.00%. During the same period last year, the firm earned ($0.76) EPS. On average, equities research analysts predict that Egalet Corporation will post ($3.52) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/07/20/egalet-corporation-eglt-getting-somewhat-favorable-media-coverage-study-shows.html.
Egalet Corporation Company Profile
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.
Receive News & Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.